无症状2型糖尿病周围神经病变患者监测血清NO和AGEs的临床意义

doi:10.3969/j.issn.2095-9400.2020.05.012

Abstract
Figure/Table
References (0)
Related Citation (10)

Download: PDF (1365 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To study the clinical significance of monitoring nitric oxide (NO) and advanced glycation end-products (AGEs) in asymptomatic type 2 diabetes mellitus (T2DM) peripheral neuropathy (DPN). Methods: From December 2015 to December 2018, a total of 80 inpatients with T2DM from the Third Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine were selected. 60 patients were diagnosed as DPN by measuring vibration perception threshold (VPT) and nerve conduction velocity (NCV), and the remaining 20 patients were in simple T2DM group. And then 60 DPN patients were further divided into symptomatic DPN group (n=29) and asymptomatic DPN group (n=31) by the presence or absence of limb numbness, burning sensation, pain and other symptoms. The levels of fasting plasma glucose (FPG), 2-hour postprandial plasma glucose (PPG), glycosylated hemoglobin (HbA1c), triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), apolipoprotein a (APOa) and apolipoprotein b (APOb) were compared among the three groups, and the results of NO and AGEs were also compared among the three groups. Results: The levels of FPG, PPG and HbA1c in symptomatic DPN group were significantly higher than those in asymptomatic DPN group and simple T2DM group (P<0.01). The levels of FPG, PPG, and HbA1c in asymptomatic DPN group were higher than those in simple T2DM group (P<0.05). There were no significant differences in the levels of TG, TC, LDL-c, HDL-c, APOa and APOb among the three groups (P>0.05). Compared with simple T2DM group, in two DPN groups the levels of serum NO were significantly decreased and the levels of serum AGEs were significantly increased (P<0.01); the levels of serum NO and AGEs were significantly different between the two DPN groups (P<0.01). Conclusion: The incidence of early asymptomatic DPN is high in clinical practice. NO and AGEs are important biological signals and effector molecules. Early detection of them will help to understand the degree of neuropathy. Controlling blood glucose is of great clinical importance in reducing the incidence of DPN.

Key words： diabetic peripheral neuropathy nitric oxide advanced glycation end-products nerve conduction velocity vibration perception threshold

Received: 20 August 2019

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	XU Yingying
	HUANG Xingyou
	WEI Zhili
	WANG Chenfang
	LIU Jingjing
	PAN Weili

URL:

https://xb.wmu.edu.cn/EN/ 10.3969/j.issn.2095-9400.2020.05.012 OR https://xb.wmu.edu.cn/EN/Y2020/V50/I5/411

[1] 林思耕, 邓宇轩, 温良, 等. 糖尿病视网膜病变危险因素分析[J]. 温州医科大学学报, 2019, 49(7): 487-490.
[2] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南 (2017年版)[J]. 中华糖尿病杂志, 2018, 10(1): 4-67.
[3] 王国凤, 徐宁, 杨涛. 经皮氧分压在2型糖尿病周围神经病变中的变化及其临床意义[J]. 中国糖尿病杂志, 2017, 25(9): 822-826.
[4] 聂发传, 石英. 糖尿病周围神经病变发生机制研究进展[J]. 重庆医学, 2015, 44(1): 122-125.
[5] 黄文智, 梁晓春. AGEs及其受体在糖尿病周围神经病变中的作用机制及药物干预研究进展[J]. 世界中西医结合杂志, 2011, 6(8): 726-728.
[6] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南 (2013年版)[J]. 中华糖尿病杂志, 2014, 6(7): 447-498.
[7] 赫广玉, 孙成林, 刘玉佳, 等. 糖尿病周围神经病变神经损害特点及相关因素分析[J]. 中国糖尿病杂志, 2014, 22(2): 118-121.
[8] GARROW A P, BOULTON A J. Vibration perception threshold-a valuable assessment of neural dysfunction in people with diabetes[J]. Diabetes Metab Res Rev, 2006, 22(5): 411419.
[9] 金兴权, 王丽萍, 张斌, 等. C肽变化与糖尿病周围神经病变的关系[J]. 山东医药, 2009, 49(37): 16-18.
[10] 宁丽娜. 振动感觉阈值检查筛查糖尿病外周神经病变的价值评估[J]. 世界最新医学信息文摘, 2015, 15(74): 88-89.
[11] 金玉华, 官俏兵, 陆旭东. 血清叶酸、维生素B12、NSE水平检测对无症状2型糖尿病周围神经病变的诊断价值[J]. 中国乡村医药, 2018, 25(2): 53-54.
[12] URICOECHEA H V, PERDOMO A B. Thyroid dysfunction and heart failure: Mechanisms and Associations[J]. Curr Heart Fail Rep, 2017, 312(5): 621-631.
[13] 杨秀颖, 张莉, 陈熙, 等. 2型糖尿病周围神经病变机制研究进展[J]. 中国药理学通报, 2016, 32(5): 598-602.
[14] 刘茜, 吴佳佳, 王菊梅, 等. 皮肤晚期糖基化终末产物与2 型糖尿病周围神经病变的相关性研究[J]. 安徽医学, 2015, 36(12): 1451-1453.
[15] 安春耀, 刘德山. 晚期糖基化终末产物与糖尿病周围神经病变关系新进展[J]. 医学综述, 2017, 23(15): 3062-3067.
[16] 汤运梁, 徐积兄. 糖基化终末产物与糖尿病慢性并发症研究进展[J]. 中国老年学杂志, 2017, 37(4): 1012-1015.
[17] 陈晓, 周晓春, 吴卫明, 等. 初诊2型糖尿病患者血清晚期糖基化终末产物、可溶性糖基化终末产物受体水平分析 [J]. 国际中医中药杂志, 2013, 35(1): 57.
[18] 李玉桂, 黄榕. α-硫辛酸治疗2型糖尿病周围神经病变的疗效及机制探讨[D]. 石河子: 石河子大学, 2016.
[19] 李玉桂, 成那, 彭程. α-硫辛酸对糖尿病周围神经病变患者血清晚期糖基化终产物的影响[J]. 中华临床医师杂志, 2016, 10(6): 790-794.
[20] 魏剑芬, 张文彦, 王颖, 等. 血清神经元特异性烯醇化酶、铁蛋白与糖尿病周围神经病变严重程度的关系[J]. 河北联合大学学报(医学版), 2016, 18(3): 186-187.
[21] 谢雯, 杨剑文, 杨晓苏, 等. 血清脂联素和一氧化氮及内皮素在糖尿病周围神经病患者中的相关性研究[J]. 中华老年心脑血管病杂志, 2014, 16(2): 185-188.
[22] 郭晶晶, 许利平, 刘凤琪, 等. 从血液相关因素评价糖痹康对糖尿病周围神经病变的干预作用[J]. 北京中医药, 2013, 32(4): 296-299.
[23] 王昌乐. 复方丹参注射液联合单唾液酸四己糖神经节苷脂钠治疗新生儿缺氧缺血性脑病疗效观察[J]. 现代中西医结合杂志, 2016, 25(20): 2257-2259.
[24] 冯彦景, 李艳君. 肌氨肽苷联合羟苯磺酸钙对糖尿病周围神经病变患者外周血ET、NO水平的影响[J]. 山东医药, 2015, 55(46): 48-49.
[25] 石清, 张冉, 杨英. 单唾液酸四己糖神经节苷脂钠注射液对糖尿病周围神经病变的临床疗效观察[J]. 中国社区医生, 2017, 33(22): 62-65.
[26] 张云霞. 数字感觉震动阈值测定在糖尿病周围神经病变中的临床应用[J]. 中国医药指南, 2017, 15(10): 57-58.
[27] 郭茜, 陈永华, 邓颖, 等. 黄芪联合川芎嗪加熏洗治疗糖尿病周围神经病变对红细胞醛糖还原酶和一氧化氮的影响 [J]. 广东医学, 2015, 36(24): 3859-3861.